Advanced Materials · 2019 · 111 citations · 23 references
PharmacyOncologyPharmacologyCancer PharmacologyChemotherapyDrug DeliveryAngiogenesis In CancerAnticancer Prodrug DesignCancer NanomedicineCombination Cancer TherapyTargeted Cancer TherapyTumor-activated ProdrugsHypoxiaMatrix Metalloproteinase-activated ProdrugsNanoparticle-based ChemotherapyReduced Systemic ToxicityTumor Microenvironment HypoxiaTumor-microenvironment Activated ProdrugsTumor-targeted Drug DeliveryTumor-targeted Prodrugs
Tumor-associated enzyme-activated prodrugs can potentially improve the selectivity of chemotherapeutics. However, the paucity of tumor-associated enzymes which are essential for prodrug activation usually limits the antitumor potency. A cooperative strategy that utilizes combretastatin A4 nanodrug (CA4-NPs) and matrix metalloproteinase 9 (MMP9)-activated doxorubicin prodrug (MMP9-DOX-NPs) is developed. CA4 is a typical vascular disrupting agent that can selectively disrupt immature tumor blood vessels and exacerbate the tumor hypoxia state. After treatment with CA4-NPs, MMP9 expression can be significantly enhanced by 5.6-fold in treated tumors, which further boosts tumor-selective active drug release of MMP9-DOX-NPs by 3.7-fold in an orthotopic 4T1 mammary adenocarcinoma mouse model. The sequential delivery of CA4-NPs and MMP9-DOX-NPs exhibits enhanced antitumor efficacy with reduced systemic toxicity compared with the noncooperative controls.
23
Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy
Quan Zhou, Shiqun Shao, Jinqiang Wang et al. · Nature Nanotechnology · 2019 · 813 citations
Pharmacy, Oncology, Pharmaceutics +12
Nanoparticles that communicate in vivo to amplify tumour targeting
Ji‐Ho Park, Kevin Lin, Neetu Singh et al. · DSpace@MIT (Massachusetts Institute of Technology) · 2010 · 505 citations · Full text
Pharmacy, Oncology, Pharmaceutics +10